Download PDF
Pharmacopsychiatry 2011; 44(05): 169-172
DOI: 10.1055/s-0031-1280793
Original Paper
Georg Thieme Verlag KG Stuttgart · New York

Body Mass Index Increase, Serum Leptin, Adiponectin, Neuropeptide Y and Lipid Levels during Treatment with Olanzapine and Haloperidol

N.R.B. Raposo
1   Laboratory of Neuroscience (LIM 27), Department and Institute of Psychiatry, Faculty of Medicine, University of São Paulo, São Paulo/SP, Brazil
2   Federal University of Juiz de Fora, Faculty of Pharmacy, Campus Universitário, Juiz de Fora/MG, Brazil
,
A.S. Ferreira
1   Laboratory of Neuroscience (LIM 27), Department and Institute of Psychiatry, Faculty of Medicine, University of São Paulo, São Paulo/SP, Brazil
,
W.F. Gattaz
1   Laboratory of Neuroscience (LIM 27), Department and Institute of Psychiatry, Faculty of Medicine, University of São Paulo, São Paulo/SP, Brazil
› Author Affiliations
Further Information

Publication History

received 19 January 2011
revised 18 April 2011

accepted 02 May 2011

Publication Date:
05 July 2011 (online)

Also available at
    Permissions and Reprints

Abstract

Introduction

Body mass index (BMI) increase is an undesired effect associated with antipsychotics, and crucial for patients’ global health and treatment compliance. We aimed to investigate the relation between BMI during olanzapine or haloperidol treatments and leptin, neuropeptide Y (NPY), adiponectin and lipid serum levels.

Methods

In this 9-month, randomized and naturalist study, 34 male patients, 18 on olanzapine and 16 on haloperidol group were enrolled, all were under monotherapy. Patient outcome was evaluated with positive and negative syndrome scale (PANSS) at every 3-month period. In each visit, BMI, leptin, NPY, lipid, olanzapine or haloperidol levels were also monitored.

Results and Discussion

Leptin levels positively correlated with BMI in olanzapine (r=0.64, p<0.001) and haloperidol (r=0.73, p<0.001) groups; only in olanzapine patients, the former also correlated with PANSS score (r=0.54, p<0.05). NPY levels negatively correlated with olanzapine levels (r=− 0.65, p<0.01). Adiponectin levels had not significantly varied.

Conclusion

Antipsychotics probably interfere on leptin and NPY signalling ways and disturb these hormones in eating behaviour control.

Key words

antipsychotic drugs - adverse effects - leptin - neuropeptide Y - adiponectin - body mass index
 

  • References

  • 1 Bernstein JG. Induction of obesity by psychotropic drugs. Ann N Y Acad Sci 1987; 499: 203-215
    PubMedGoogle Scholar
  • 2 Baptista T, Lacruz A, de Mendonza S et al. Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones. Pharmacopsychiatry 2000; 33: 81-88
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Parsons B, Allison DB, Loebel A et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res 2009; 110: 103-110
    CrossrefPubMedGoogle Scholar
  • 4 Wirshing DA, Wirshing WC, Kysar L et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60: 358-363
    CrossrefPubMedGoogle Scholar
  • 5 Kraus T, Haack M, Schuld A et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999; 156: 312-314
    PubMedGoogle Scholar
  • 6 Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms. Pharmacol Ther 2010; 125: 169-179
    CrossrefPubMedGoogle Scholar
  • 7 Valassi E, Scacchi M, Cavagnini F. Neuroendocrine control of food intake. Nutr Metab Cardiovasc Dis 2008; 18: 158-168
    CrossrefPubMedGoogle Scholar
  • 8 Jin H, Meyer JM, Mudaliar S et al. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res 2008; 100: 70-85
    CrossrefPubMedGoogle Scholar
  • 9 De Leon J, Susce MT, Jonhson M et al. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr Res 2007; 92: 95-102
    CrossrefPubMedGoogle Scholar
  • 10 Mukherjee S, Decina P, Bocola V et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996; 37: 68-73
    Google Scholar
  • 11 Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition Washington, DC: American Psychiatric Press; 1994
    Google Scholar
  • 12 Kay SR, Opler LA, Lindenmayer JP. The positive and negative syndrome scale (PANSS): rationale and standardization. Br J Psychiatry 1989; 155: 59-65
    PubMedGoogle Scholar
  • 13 Olesen OV, Linnet K. Determination of olanzapine in serum by high-performance liquid chromatography using ultraviolet detection considering the easy oxidability of the compound and the presence of other psychotropic drugs. J Chromatogr B Biomed Sci Appl 1998; 714: 309-315
    CrossrefPubMedGoogle Scholar
  • 14 Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000; 61: 742-749
    CrossrefPubMedGoogle Scholar
  • 15 Morimoto T, Yamamoto Y, Mobarakeh JI et al. Involvement of the histaminergic system in leptin-induced suppression of food intake. Physiol Behav 1999; 67: 679-683
    CrossrefPubMedGoogle Scholar
  • 16 Dryden S, Brown M, King P et al. Decreased plasma leptin levels in lean and obese Zucker rats after treatment with the serotonin reuptake inhibitor fluoxetine. Horm Metab Res 1999; 31: 363-366
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Meguid MM, Fetssov SO, Varma M et al. Hypothalamic dopamine and serotonin in the regulation of food intake. Nutrition 2000; 16: 843-857
    CrossrefPubMedGoogle Scholar
  • 18 Leibowitz SF, Alexander JT. Hypothalamic serotonin in control of eating behavior, meal size, and body weight. Biol Psychiatry 1998; 44: 851-864
    CrossrefPubMedGoogle Scholar
  • 19 Marquina D, Peña R, Fernández E et al. Int Clin Psychopharmacol 2011; 26: 169-172
    CrossrefPubMed
  • 20 Näslund E, Hellström PM. Appetite signaling: From gut peptides and enteric nerves to brain. Physiol Behav 2007; 92: 256-262
    CrossrefPubMedGoogle Scholar
  • 21 Considine RV, Sinha MK, Heiman ML et al. Serum immunoreactive-leptin concentrations in normal weight and obese humans. N Engl J Med 1996; 334: 292-295
    CrossrefPubMedGoogle Scholar
  • 22 Foutaine RJ, Taylor AE, Mancuso JP et al. Increased food intake and energy expenditure following administration of olanzapine to healthy men. Obesity 2010; 18: 1646-1651
    CrossrefPubMedGoogle Scholar
  • 23 Kluge M, Schuld A, Schacht A et al. Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrino 2009; 34: 118-128
    CrossrefPubMedGoogle Scholar
  • 24 Esen-Danaci A, Sarandõi A, Tanellu F et al. Effects of second generation antipsychotics on leptin and ghrelin. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1434-1438
    CrossrefPubMedGoogle Scholar
  • 25 Kim B, Sohn J, Park C et al. Body weight and plasma levels of ghrelin and leptin during treatment with olanzapine. J Korean Med Sci 2008; 23: 685-690
    CrossrefPubMedGoogle Scholar
  • 26 Chaggar PS, Shaw SM, Williams SG. Effect of antipsychotic medications on glucose and lipid levels. J Clin Pharmacol 2010; doi: DOI: 10.1177/0091270010368678.
    PubMedGoogle Scholar
  • 27 Monteleone P, Martiadis V, Maj M. Management of schizophrenia with obesity, metabolic, and endocrinological disorders. Psychiatr Clin North Am 2009; 32: 775-794
    CrossrefPubMedGoogle Scholar
  • 28 Kolakowska T, Gadhvi H, Molyneux S. An open clinical trial of fenfluramine in chronic schizophrenia: a pilot study. Int J Clin Psychopharmacol 1987; 2: 83-88
    CrossrefPubMedGoogle Scholar
  • 29 Knox JM. A study of weight reducing diets in psychiatric in-patients. Br J Psychiatry 1980; 136: 287-289
    CrossrefPubMedGoogle Scholar
  • 30 Rotatori AF, Fox R, Wicks A. Weight loss with psychiatric residents in a behavioral self-control program. Psychol Rep 1980; 6: 483-486
    PubMedGoogle Scholar
  • 31 Ugur T, Bartels M, Kis B et al. Psychosis following anti-obesity treatment with rimonabant. Obes Facts 2008; 1: 103-105
    CrossrefPubMedGoogle Scholar